Gary K. Lee - Feb 10, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Feb 10, 2025
Transactions value $
$0
Form type
4
Date filed
2/26/2025, 07:27 PM
Previous filing
Feb 13, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +113K +175.24% $0.00 177K Feb 10, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +450K $0.00 450K Feb 10, 2025 Common Stock 450K $0.55 Direct F3
transaction LYEL Option (right to buy) Award $0 +56.3K $0.00 56.3K Feb 10, 2025 Common Stock 56.3K $0.55 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2 Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan.
F3 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F4 The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.